Novartis details benefit of Afinitor with Aromasin in breast cancer
This article was originally published in Scrip
Afinitor (everolimus) has been shown to boost hormonal therapy for advanced breast cancer in postmenopausal women, according to trial results released today by Novartis at the 2011 European Multidisciplinary Cancer Congress (EMCC) in Stockholm, Sweden.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.